Dianabol: The Original Mass Builder — Educational Reference
Last updated: March 2026
Methandienone (Dianabol) was the first widely used oral anabolic-androgenic steroid, developed in 1958. This educational reference covers its pharmacology, documented clinical effects, significant hepatotoxicity risks, estrogenic activity, and post-cycle therapy requirements for harm reduction.
(vs testosterone = 100:100)
Oral, per day
Multiple daily doses typical
📋 On this page
How Methandienone Works
Methandienone is a synthetic derivative of testosterone with a methyl group at C-17 (enabling oral activity) and a double bond between C-1 and C-2 (reducing androgenic activity relative to testosterone, slightly).
Methandienone binds to androgen receptors (AR) with moderate affinity — roughly 56% that of testosterone. Despite lower AR binding affinity, its anabolic effects are amplified because it is NOT efficiently bound by sex hormone-binding globulin (SHBG), leaving a greater free fraction active at tissue level.
The C-17α methyl group prevents first-pass hepatic metabolism that would otherwise destroy oral testosterone. This makes Dianabol orally active — but at a cost. This modification creates reactive metabolites that cause hepatocyte stress, elevated transaminases (ALT/AST), and risks of cholestasis and peliosis hepatis with prolonged use.
Methandienone aromatizes to 17α-methyl estradiol — a potent estrogen that is also resistant to hepatic inactivation. This drives significant estrogenic effects: water retention (often 5–10 lbs), gynecomastia risk, and blood pressure elevation due to sodium retention. Aromatase inhibitors are commonly required to mitigate these effects.
Like all exogenous androgens, methandienone suppresses the hypothalamic-pituitary-testicular axis. Endogenous LH and FSH drop, leading to testicular atrophy and cessation of natural testosterone production. HPTA recovery after cessation requires weeks to months; PCT with SERMs (Nolvadex/Clomid) is standard harm reduction practice.
What Clinical Literature Shows
Data from published clinical trials, case series, and pharmacological studies on methandienone.
Side Effects & Risks
Key Takeaways
- Produces significant lean mass and strength gains in short timeframes
- Anabolic:androgenic ratio of ~90–210:40–60 vs testosterone baseline
- Half-life of 3–5 hours requires multiple daily doses
- 17α-alkylation guarantees oral bioavailability but causes liver toxicity
- Heavy aromatization to 17α-methyl estradiol — requires aromatase inhibitor
- HPTA suppression is profound and rapid — PCT is mandatory
- Cycle length limited to 4–6 weeks due to hepatotoxicity
- Long-term cardiovascular outcomes in recreational users not well documented
- Optimal liver protection protocols (TUDCA, NAC dosing) not established by RCTs
- Individual genetic variation in hepatic metabolism creates unpredictable toxicity
- Interaction effects with other compounds poorly characterized
- Peliosis hepatis risk threshold — may occur at any dose
🛒 Liver Support & Monitoring
If using any 17α-alkylated oral compound, liver support and regular bloodwork are essential harm reduction measures.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and harm reduction purposes only. It is not medical advice. Methandienone (Dianabol) is a Schedule III controlled substance in the United States under the Anabolic Steroid Control Act of 1990. Possession, distribution, or use without a valid prescription is illegal and carries serious legal penalties. Anabolic steroids carry significant health risks including liver damage, cardiovascular disease, and hormonal disruption. Always consult a qualified physician before making any decisions regarding hormone use. HighPeptides does not endorse or encourage the use of controlled substances.